According to the latest market research study released by Technavio, the global viscosupplementation market is expected to grow at a CAGR of more than 6% during the forecast period 2016-2020.
This market research report by Technavio provides an in-depth analysis of the market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Click here to request a free sample of this report
Technavio research analysts categorize the global viscosupplementation market based on products:
Global viscosupplementation market share by products 2015
|
Three-injection cycle |
36.4% |
|
Five-injection cycle |
35.5% |
|
Single-injection cycle |
28.1% |
Source: Technavio
Three-injection cycle market
The three-injection cycle segment occupied the maximum share in the products segment of the global viscosupplementation market, accounting for around 36% share in 2015. This segment is expected to dominate the market during the forecast period, due to the low-cost products and the shorter treatment regimen as compared to other products. The three-injection cycle products are used in intra-articular viscosupplementation for the treatment of knee osteoarthritis, wherein the hyaluronic acid is injected into the knee of the patient per week for three weeks. Three-injection cycle products are extensively used in France, Italy, the US, Spain, and Germany, where the compensation of single-injection cycle products are not fully covered. Some of the well-known three- injection cycle products are ORTHOVISC, Euflexxa, Supartz, MONOVISC, and Synvisc. Synvisc three-injection cycle product is extensively used in France, Italy, and Germany, followed by Laboratoires Genevrier three/five-injection cycle product, and Sinovial three-injection cycle product.
“Vendors in the three-injection cycle market are focusing on expanding their geographical presence to cater to the larger market globally. In fact, numerous emerging vendors through constant product innovations are focusing on strengthening their position in the market. Some of the major vendors in the three-injection cycle market are Anika Therapeutics, Ferring Pharmaceuticals, Seikagaku, and Sanofi,” says Amber Chourasia, senior analyst at Technavio for research on health and wellness.
Five-injection cycle market
The global five-injection cycle market is likely to benefit from an increased demand for viscosupplements, especially from the emerging economies due to the increased awareness of knee osteoarthritis. However, the market is expected to experience slow growth as compared to other product segments during the forecast period due to the shift in consumer preference from five-injection cycle products to single- and three-injection cycle products. Five-injection cycle products are less expensive as compared to three-injection cycle and single-injection cycle products. Some of the key vendors offering five-injection cycle products are Fidia Farmaceutici, Seikagaku, and Sanofi and the eminent products are Supartz, Hyalgen, and GenVisc 850.
Single-injection cycle market
The single-injection cycle viscosupplements are innovative and help cure knee osteoarthritis in a single injection. It is an evolving product segment as it requires fewer hospital visits and cures knee osteoarthritis for six months. Countries such as Italy, Spain, France, the UK, Germany, the US, Japan, and Canada are increasingly adopting single-injection viscosupplements. Owing to the shift in consumer preference, the single-injection cycle market is anticipated to experience the fastest growth during the forecast period. The consumers are widely opting for single-injection cycle products because of the shorter treatment regimen and convenience offered by these products. These products are showing high growth mostly in the Americas, due to many patients undergoing knee surgery. These viscosupplements are used in intra-articular viscosupplementation for the treatment of knee osteoarthritis, wherein, hyaluronic acid is introduced into the knee joints through a single injection. Its dosage is safe, less painful, and has limited side effects compared to invasive knee replacement surgeries. The rise in demand for single-injection cycle viscosupplements has compelled the companies to focus on promoting their products by expanding in the US market. The vendors mostly focus on R&D to introduce new single-injection cycle products in emerging markets such as APAC. It is expected that the technological enhancements and high investments by market vendors to develop cheaper single-injection viscosupplements, will boost the demand in the market. The key vendors offering single-injection products are Anika Therapeutics, Sanofi, and Fidia Farmaceutici and the key products are Synvisc-One, Genvisc 850, Hylan GF-20, ORTHOVISC, and Gel-One.
The top leading vendors operating in the global viscosupplementation market are:
- Sanofi
- Anika Therapeutics
- Seikagaku
- Fidia Farmaceutici
- Ferring Pharmaceuticals
Other prominent vendors in the market include Allergan, Contipro Biotech, DePuy Synthes, F. Hoffmann-La Roche, Galderma, HTL Biotechnology, Hyaltech, Expanscience Laboratoires, Lifecore Biomedical, Lipo Chemicals, Merz Aesthetics, Mylan, Nordic Drugs, Shandong Freda Biochem, Shanghai Jingfeng Pharmaceutical, Smith & Nephew, TEIJIN PHARMA, and TRB Chemedica International.
A more detailed analysis is available in the Technavio report titled, ‘Global Viscosupplementation Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Knee Implant market 2015-2019
- Global Orthopedic Devices Market 2016-2020
- Global Bioactive Materials Market 2016-2020
- Global Foot Drop Implants Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
